Profile data is unavailable for this security.
About the company
Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). It operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.
- Revenue in USD (TTM)0.00
- Net income in USD-6.01m
- Incorporated1994
- Employees1.00
- LocationProtagenic Therapeutics Inc149 FIFTH AVENUE, SUITE 500NEW YORK 10010United StatesUSA
- Phone+1 (212) 994-8200
- Fax+1 (302) 636-5454
- Websitehttps://protagenic.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aditxt Inc | 506.45k | -41.45m | 2.69m | 47.00 | -- | 0.2264 | -- | 5.31 | -109.80 | -109.80 | 0.7488 | 5.96 | 0.0284 | 0.9296 | 1.34 | 10,775.53 | -231.82 | -192.78 | -658.00 | -321.59 | -27.22 | -- | -8,149.75 | -7,208.65 | 0.0562 | -3.42 | 0.3915 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
Novelstem International Corp | 15.00k | -4.22m | 2.81m | 15.00 | -- | -- | -- | 187.53 | -0.09 | -0.09 | 0.0003 | -0.0478 | 0.0065 | -- | 10.00 | -- | -172.16 | -- | -1,011.77 | -- | -- | -- | -26,418.53 | -- | -- | -8.40 | 2.34 | -- | 0.00 | -- | -446.84 | -- | -- | -- |
Qualigen Therapeutics Inc | 0.00 | -11.33m | 2.90m | 4.00 | -- | -- | -- | -- | -2.16 | -2.22 | 0.00 | -0.5417 | 0.00 | -- | -- | 0.00 | -133.27 | -- | -800.31 | -- | -- | -- | -- | -- | -- | -4.14 | -- | -- | -- | -- | 10.22 | -- | -- | -- |
Bio Path Holdings Inc | 0.00 | -13.96m | 2.93m | 10.00 | -- | -- | -- | -- | -27.39 | -27.39 | 0.00 | -3.48 | 0.00 | -- | -- | 0.00 | -216.97 | -70.80 | -390.65 | -76.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -15.94 | -- | -- | -- |
Petros Pharmaceuticals Inc | 4.69m | -20.46m | 2.94m | 21.00 | -- | 0.2953 | -- | 0.6265 | -7.37 | -7.37 | 1.68 | 1.55 | 0.1542 | 0.7858 | 2.15 | 223,487.10 | -29.37 | -32.43 | -41.80 | -68.05 | 69.91 | 62.04 | -190.50 | -201.70 | 1.46 | -- | 0.4284 | -- | -2.83 | -16.15 | 31.06 | -- | -- | -- |
Finch Therapeutics Group Inc | 0.00 | -16.28m | 2.99m | 18.00 | -- | 0.1569 | -- | -- | -10.14 | -10.14 | 0.00 | 11.86 | 0.00 | -- | -- | -- | -25.22 | -- | -28.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
Alzamend Neuro Inc | 0.00 | -12.40m | 3.04m | 4.00 | -- | -- | -- | -- | -18.70 | -18.70 | 0.00 | -5.72 | 0.00 | -- | -- | 0.00 | -267.15 | -- | -880.90 | -- | -- | -- | -- | -- | -- | -1,352.90 | -- | -- | -- | -- | -20.35 | -- | -- | -- |
CNS Pharmaceuticals Inc | 0.00 | -17.46m | 3.07m | 3.00 | -- | -- | -- | -- | -179.17 | -179.17 | 0.00 | -20.76 | 0.00 | -- | -- | 0.00 | -384.86 | -132.47 | -- | -185.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.42 | -- | -- | -- |
Lipella Pharmaceuticals Inc | 477.45k | -4.74m | 3.07m | 5.00 | -- | 1.11 | -- | 6.44 | -0.7633 | -0.7633 | 0.0747 | 0.3638 | 0.1232 | -- | 6.25 | 95,490.00 | -122.37 | -- | -146.33 | -- | -- | -- | -993.39 | -- | -- | -- | 0.00 | -- | 144.15 | -- | -77.81 | -- | -- | -- |
Actavia Life Sciences Inc | 0.00 | -406.65k | 3.09m | 1.00 | -- | -- | -- | -- | -0.0005 | -0.0005 | 0.00 | -0.0028 | 0.00 | -- | -- | 0.00 | -805.97 | -158.17 | -- | -- | -- | -- | -- | -- | -- | -5.63 | -- | -- | -- | -- | -547.04 | -- | -- | -- |
Protagenic Therapeutics Inc | 0.00 | -6.01m | 3.11m | 1.00 | -- | 1.46 | -- | -- | -1.37 | -1.37 | 0.00 | 0.4808 | 0.00 | -- | -- | 0.00 | -117.26 | -74.49 | -140.56 | -92.56 | -- | -- | -- | -- | -- | -11.50 | 0.00 | -- | -- | -- | -40.64 | -- | -- | -- |
Aptevo Therapeutics Inc | 0.00 | -27.31m | 3.17m | 40.00 | -- | 0.0454 | -- | -- | -98.49 | -97.90 | 0.00 | 9.06 | 0.00 | -- | -- | 0.00 | -103.85 | -47.16 | -134.86 | -85.03 | -- | -- | -- | -583.47 | -- | -- | 0.00 | -- | -100.00 | -- | -365.90 | -- | -- | -- |
Zyversa Therapeutics Inc | 0.00 | -105.53m | 3.21m | 7.00 | -- | 0.2864 | -- | -- | -1,791.54 | -1,791.54 | 0.00 | 13.44 | 0.00 | -- | -- | 0.00 | -142.87 | -- | -164.77 | -- | -- | -- | -- | -- | -- | -17,576.86 | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
Virax Biolabs Group Ltd | 0.00 | -1.71m | 3.24m | 5.00 | -- | -- | -- | -- | -1.50 | -1.50 | 0.00 | -0.8568 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | 0.0223 | -112.29 | -- | -- | -100.00 | -- | -162.50 | -- | -- | -- |
Ensysce Biosciences Inc | 1.75m | -11.55m | 3.25m | 7.00 | -- | 0.8365 | -- | 1.86 | -3.74 | -3.74 | 0.5109 | 0.5115 | 0.3886 | -- | 9.06 | 249,514.30 | -257.00 | -17.68 | -574.02 | -19.42 | -- | -- | -661.34 | -715.78 | -- | -6.25 | 0.0671 | -- | -11.61 | -- | 57.64 | -- | -- | -- |
GB Sciences Inc | 0.00 | -4.03m | 3.35m | 3.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0119 | 0.00 | -- | -- | 0.00 | -255.86 | -49.16 | -- | -131.40 | -- | 6.03 | -- | -995.19 | -- | -8.63 | -- | -- | -- | -- | -2,715.25 | -- | -60.82 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 32.00k | 0.72% |
Geode Capital Management LLCas of 31 Mar 2024 | 25.17k | 0.57% |
Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 21.41k | 0.48% |
FNY Capital Management LPas of 31 Mar 2024 | 18.75k | 0.42% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 13.81k | 0.31% |
Tower Research Capital LLCas of 31 Mar 2024 | 5.81k | 0.13% |
Vanguard Global Advisers LLCas of 31 Mar 2024 | 1.17k | 0.03% |
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 27.00 | 0.00% |
CWM LLCas of 30 Jun 2024 | 1.00 | 0.00% |
Bank of America, NA (Private Banking)as of 31 Mar 2024 | 1.00 | 0.00% |